Investor Presentation

Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 07 July 2026 National Stock Exchange of India Limited BSE Limited Scrip Symbol: SUNPHARMA Scrip Code: 524715 Subject: Investor Presentation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the investor presentation, which we shall be uploading on our website after sending this letter to you. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA Reaching People. Touching Lives Creating Lasting Value Investor Presentation – June 2026 NSE:SUNPHARMA | BSE:524715 | Bloomberg:SUNP IN | Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. © Sun Pharmaceutical Industries Limited. All Rights Reserved. 2 Sun Pharma 1 Revenue composition and growth highlights 2 Business operations 3 R&D & Manufacturing 4 Corporate Governance 5 Key Financials 6 Company history and key deals 7 Focus areas © Sun Pharmaceutical Industries Limited. All Rights Reserved. 3 Sun Pharma at a glance Leading global specialty generic company Global presence Operates in over 100 countries Diversified business Innovative Medicines, branded generics, generics & APIs Innovative Medicines Fast growing. Focused therapy approach. US Generics 13th largest in US generics market## India Largest pharma company in India** Emerging Markets Operating at scale in over 80 countries Rest of World Expanding presence in Ex-US developed markets R&D Global clinical trials. Early-stage novel R&D. Generic R&D Manufacturing capabilities across injectables, sprays, ointments, 40 Manufacturing facilities creams, liquids, tablets and capsules Quality compliance Several facilities approved by global regulators incl. USFDA Employees 47,000+ global employee base ## Source: IQVIA data for 12 months ended Mar 2026 ** As per AIOCD AWACS data for 12 months ended Mar 2026 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 4 A diversified revenue base Emerging Markets Rest of World (RoW)# Formulations Formulations 19% 15% API & Others FY26 Sales Rs 582 Bn India Formulations US Formulations # Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets. © Sun Pharmaceutical Industries Limited. All Rights Reserved. 5 Impressive track record of growth (All Figures in Rs Bn) CAGR for FY10-FY25 279 82 85 Adjusted Sales EBITDA 52 Net Profit CAGR CAGR CAGR 57 17% 20 16% 18 14% FY11 FY16 FY21 FY26 FY11 FY16 FY21 FY26 FY11 FY16 FY21 FY26 Adjusted 67 62 Operating Free Cash 22 25 EPS Cash Flow 50 Flow (Rs/Share) 24 CAGR CAGR CAGR 12% 11% 14% FY11 FY16 FY21 FY26 FY11 FY16 FY21 FY26 FY11 FY16 FY21 FY26 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 6 Strong profitability and return ratios Adjusted Net Profit Gross Margin # EBITDA Margin Margin 22.8% 77.7% 79.3% 80.2% 30.3% 19.8% 19.7% 20.8% 21.2% 75.4% 29.0% 73.1% 26.9% 26.9% 26.5% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 ROCE ROE Market Cap (USD Bn) 17.4% 20.4% 20.7% 47.0 48.6 45.1 18.2% 16.7% 16.4% 16.5% 15.9% 15.9% 29.5 29.4 15.0% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 # Gross margin= (Sales - Material Cost)/Sales*100) ROCE & ROE exclude one-time exceptional charges ROCE = EBIT / Average of (Total Assets – Current Liabilities) ROE = Net Profit / Average Shareholders Equity (Market Cap as on 31st March) © Sun Pharmaceutical Industries Limited. All Rights Reserved. 7 Best-in-class profitability Sun Pharma Range of Top 9 Indian Pharma Cos. Average Gross Margin EBITDA Margin Adjusted Net Profit Margin 67% 27% 27% 66% 23% 20% 21% 26% 25% 21% 18% 17% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Gross margin= (Net Sales – Material Cost) / Net Sales * 100 #Top 9 Indian Pharma companies include Cipla, Dr. Reddy’s, Aurobindo, Zydus Lifesciences, Torrent, Alkem Labs, Lupin, Mankind and Divis Lab. © Sun Pharmaceutical Industries Limited. All Rights Reserved. 8 Business operations © Sun Pharmaceutical Industries Limited. All Rights Reserved. 9 Snapshot of business operations US Formulations India Formulations ⚫ FY26 sales: Rs 168,242 mn ⚫ FY26 sales: Rs 192,904 mn ⚫ Innovative Medicines & Generics. Over 600 approved ⚫ Largest pharma company in India with 8.4% market products share ⚫ Large part of Innovative Medicines sales in the US. ⚫ No.1 with 11 classes of prescribers ⚫ 13th largest generics company in US*, strong pipeline EM Form RoW Form# India 19% 34% • Gross sales: Rs 582,201 mn 15% la • EBITDA: Rs 177,314 mn (30.3% margin) FY26 c ih p at ilp • R&D investment: 6.1% of Sales eune FY26 API & 4 %Others r gs • Innovative Medicines share 22% of sales s G • Strong balance sheet r India Form • Market cap: US$ 45 Bn (1) US Form International 29% Emerging Markets (EM) Formulations Rest of World (RoW) Formulations ⚫ FY26 sales: Rs 111,865 mn ⚫ FY26 sales: Rs 85,684 mn ⚫ Over 80 countries across 5 continents ⚫ Western Europe, Canada, Japan, Israel, A&NZ+ ⚫ Romania, Russia, South Africa, Brazil & Mexico are focus ⚫ Innovative Medicines & Generics. Differentiated offering markets for hospitals Note: (1) As of May 26, 2026, using spot exchange rate of INR /USD = 95.44 # Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel, and other markets. * Source: IQVIA data for 12 months ended Mar 2026 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 10 Driving sustainable long-term growth Balance profitability & Sustainable growth investments • Achievecritical massinkey markets • Increase contribution of Innovative andcomplex products • Embedsustainabilitypractices inbusiness • Direct futureinvestmentstowards • Actionable targets onsustainability differentiated products Cost leadership Business Development • Optimize operationalcosts • Useacquisitionsto bridgegaps whileyieldingtarget ROI • Leveragebenefitsof vertically • Focusonaccessto novelproducts, integrated operations technology or market presence © Sun Pharmaceutical Industries Limited. All Rights Reserved. 11 ESG Performance - FY 2024-25 Environmental Social Governance Energy Employee wellbeing Corporate Governance • 41% Energy sourced from • 6,978 new hires • 92.9% Average Board meeting renewable sources • 18.59% gender diversity attendance • 21% reduction in absolute Scope 1 • 0 fatalities • 62.5% Independent board and Scope 2 emissions compared directors* to baseline year 2020 Corp [Showing first 8,000 characters — download PDF for full document]